PRGN-3006 T Cells
Phase 1Active 2 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Trial Timeline
May 20, 2019 → Aug 1, 2025
NCT ID
NCT03927261About PRGN-3006 T Cells
PRGN-3006 T Cells is a phase 1 stage product being developed by Precigen for Acute Myeloid Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT03927261. Target conditions include Acute Myeloid Leukemia, Myelodysplastic Syndromes.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03927261 | Phase 1 | Active |
Competing Products
20 competing products in Acute Myeloid Leukemia